# Integer Holdings Corp: Form 10-Q for the period ended Oct 2, 2015

- Company: [Integer Holdings Corp](/companies/itgr.md) (CIK 1114483)
- Form: 10-Q
- Filed: 2015-11-10
- Accepted by EDGAR: Nov 10, 2015, 14:16 ET
- Period: 2015-10-02
- Accession: 0001114483-15-000018
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1114483/000111448315000018/gb-2015100210q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114483/000111448315000018/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-10-02.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-07-04 to 2015-10-02 | $146.6m | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2015-01-03 to 2015-10-02 | $482.8m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2015-07-04 to 2015-10-02 | $95.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2015-01-03 to 2015-10-02 | $320.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2015-07-04 to 2015-10-02 | $51.6m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2015-01-03 to 2015-10-02 | $162.0m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2015-07-04 to 2015-10-02 | $22.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2015-01-03 to 2015-10-02 | $69.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2015-07-04 to 2015-10-02 | $1.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2015-01-03 to 2015-10-02 | $23.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2015-07-04 to 2015-10-02 | $5.8m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2015-01-03 to 2015-10-02 | $8.2m | us-gaap:InterestExpense |
| Income tax | 3 months, 2015-07-04 to 2015-10-02 | −$16.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2015-01-03 to 2015-10-02 | $4.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2015-07-04 to 2015-10-02 | $22.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2015-01-03 to 2015-10-02 | $17.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-07-04 to 2015-10-02 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2015-01-03 to 2015-10-02 | $0.66 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-07-04 to 2015-10-02 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2015-01-03 to 2015-10-02 | $0.68 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-07-04 to 2015-10-02 | 26,441,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2015-01-03 to 2015-10-02 | 26,372,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2015-01-03 to 2015-10-02 | $31.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2015-01-03 to 2015-10-02 | $31.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2015-10-02 | $68.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-10-02 | $364.3m | us-gaap:AssetsCurrent |
| Total assets | at 2015-10-02 | $983.6m | us-gaap:Assets |
| Current liabilities | at 2015-10-02 | $117.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-10-02 | $337.8m | us-gaap:Liabilities |
| Long-term debt | at 2015-10-02 | $165.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2015-10-02 | $15.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2015-10-02 | $645.9m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 66,601 characters.

### Our Business

We have two reportable segments: Greatbatch Medical and QiG Group (“QiG”). Greatbatch Medical designs and manufactures products where Greatbatch either owns the intellectual property or has unique manufacturing and assembly expertise. These products include medical devices and components for the cardiac, neuromodulation, orthopaedics, portable medical, vascular, and energy markets among others. Our Greatbatch Medical segment also offers value-added assembly and design engineering services for medical devices that utilize its component products.

QiG is a medical device company formed in 2008 to develop and commercialize a neurostimulation technology platform for treatment of various disorders by stimulating tissues associated with the nervous system. QiG is in the process of developing applications for its neurostimulation technology platform for emerging indications such as spinal cord stimulation (“SCS”), sacral nerve stimulation (“SNS”), and deep brain stimulation (“DBS”), among others. QiG’s Algostim, LLC (“Algostim”) subsidiary is focused on the development and commercialization of its Algovita SCS system (“Algovita”), the first application of its neurostimulation technology platform and is indicated for the treatment of chronic pain of the trunk and limbs. QiG’s PelviStim LLC (“PelviStim”) subsidiary is focused on the commercialization of QiG’s neurostimulation technology platform for SNS. QiG revenue includes sales of neural interface technology, components and systems to the neuroscience and clinical markets from Greatbatch’s NeuroNexus Technologies, Inc. (“NeuroNexus”) subsidiary. Our QiG segment also includes the results of Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”), a neuromodulation medical device developer and manufacturer for development stage companies acquired by Greatbatch in August 2014.

On July 30, 2015, we announced a proposed spin-off of a portion of our QiG segment through a tax-free distribution of all of the shares of our QiG Group LLC subsidiary to the stockholders of Greatbatch on a pro rata basis (the “Spin-off”). Immediately prior to completion of the Spin-off, QiG Group LLC will be converted into a corporation and change its name to Nuvectra Corporation (“Nuvectra”). The portion of the QiG segment being spun-off is expected to be comprised of QiG Group LLC and its subsidiaries: (i) Algostim, (ii) PelviStim, and (iii) Greatbatch’s NeuroNexus subsidiary. Upon completion of the Spin-off, Nuvectra will be an independent, publicly-traded company and Greatbatch will not own any shares of Nuvectra common stock but will retain the operations of QiG not spun-off, which includes CCC.

### Our Acquisitions

On August 12, 2014, we purchased all of the outstanding common stock of CCC, headquartered in Montevideo, Uruguay. CCC is an active implantable neuromodulation medical device systems developer and manufacturer that produces a range of medical devices including implantable pulse generators, programmer systems, battery chargers, patient wands, and leads. This acquisition allows us to more broadly partner with medical device companies, complements our core discrete technology offerings, and enhances our medical device innovation efforts. The operating results of CCC were included in our QiG segment from the date of acquisition. Once the medical devices developed by CCC for development stage companies receives regulatory approval and reaches significant production levels, the responsibility for manufacturing these products may be transferred to Greatbatch Medical. The aggregate purchase price of CCC was $19.8 million, which we funded with cash on hand. Total assets acquired from CCC were $26.2 million. Total liabilities assumed from CCC were $6.4 million.

On October 27, 2015, we acquired all of the outstanding common stock of Lake Region Medical Holdings, Inc. (“Lake Region Medical”) for a total purchase price including debt assumed of approximately $1.77 billion. Lake Region Medical offers fully integrated outsourced manufacturing and engineering services, contract manufacturing, finished device assembly, original device development and supply chain management services from concept to point-of-care in the cardio & vascular and advanced surgical markets. After completing the acquisition, we are now one of the largest medical device outsource (“MDO”) manufacturers in the world. As a result of the Lake Region Medical acquisition and proposed Spin-off, we are reevaluating our operating and reporting segments. See Note 17 “Subsequent Events” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information regarding this transaction and the significant impact it will have on our financial position and results of operations.

### Our Customers

Our products are designed to provide reliable, long-lasting solutions that meet the evolving requirements and needs of our customers. The nature and extent of our selling relationships with each customer is different in terms of breadth of products purchased, purchased product volumes, length of contractual commitment, ordering patterns, inventory management and selling prices.

Our Greatbatch Medical customers include large multi-national original equipment manufacturers (“OEMs”), such as Biotronik, Boston Scientific, Cyberonics, Halliburton Company, Johnson & Johnson, Medtronic, Philips Healthcare, Smith & Nephew, Sorin Group, St. Jude Medical, Stryker, Zimmer Biomet, and Zoll. For the nine months ended October 2, 2015, Johnson & Johnson, Medtronic, and St. Jude Medical collectively accounted for 50% of our total sales.

- 29 -

QiG customers include numerous scientists, hospitals, and universities throughout the world. Additionally, with the acquisition of CCC, QiG customers also include various research companies and institutes and early stage medical device companies.

### Financial Overview

Sales for the third quarter and first nine months of 2015 decreased 15% and 7%, respectively, in comparison to the prior year period. Sales for the third quarter and first nine months of 2015 include $1.5 million and $6.6 million, respectively, from CCC, which was acquired in August 2014. Sales for the third quarter and first nine months of 2015 also include the impact of foreign currency exchange rate fluctuations, which reduced sales by approximately $2.5 million and $12.0 million, respectively, in comparison to the prior year periods, due to the strengthening dollar versus the Euro. Excluding the impact of these items, our organic constant currency sales decreased 13% and 6% for the third quarter and first nine months of 2015 in comparison to the prior year periods, respectively. The third quarter and first nine months of 2015 organic constant currency sales decrease was primarily due to lower cardiac and neuromodulation and energy sales, which were impacted by the timing of new product introductions and faster than anticipated runoff of end of life products, customer inventory management programs, as well as a slowdown in the energy markets.

We prepare our condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Additionally, we consistently report and discuss in our earnings releases and investor presentations adjusted net income, adjusted earnings per diluted share, EBITDA, adjusted EBITDA and organic constant currency growth rates. These adjusted amounts, other than EBITDA, adjusted EBITDA and organic constant currency sales growth rates, consist of GAAP amounts adjusted for the following to the extent occurring during the period: (i) acquisition-related charges, (ii) amortization of intangible assets (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain litigation expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) gain/loss on cost and equity method investments, (ix) the income tax (benefit) related to these adjustments and (x) certain tax items related to the Federal research and development tax credit which are outside the normal benefit received. Adjusted earnings per diluted share are calculated by dividing adjusted net income by diluted weighted average shares outstanding. Adjusted EBITDA consists of GAAP net income plus (i) the same adjustments as listed above except for (ix) and (x), (ii) GAAP stock-based compensation expense, interest expense, depreciation and amortization (less adjustments already excluded in the items listed above), (iii) GAAP provision (benefit) for income taxes and (iv) non-cash gains (losses) from cost and equity method investments. To calculate organic constant currency sales growth rates, which exclude the impact of changes in foreign currency exchange rates, as well as the impact of any acquisitions or divestitures of product lines on sales growth rates, we convert current period sales from local currency to U.S. dollars using the previous periods’ foreign currency exchange rates and exclude the amount of sales acquired/divested during the period from the current/previous period amounts, respectively. We believe that the presentation of adjusted net income, adjusted diluted earnings per share, EBITDA, adjusted EBITDA and organic constant currency sales growth rates provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations. Additionally, these measures are used by management to forecast and evaluate the operational performance of the Company and compliance with our debt agreements. Additionally, incentive compensation targets for our associates are based upon adjusted measures.

- 30 -

A reconciliation of GAAP net income and diluted earnings per share (“EPS”) to adjusted amounts is as follows (in thousands, except per share amounts):

|  | Three Months Ended October 2, 2015 Net Income | Per Diluted Share | October 3, 2014 Net Income | Per Diluted Share | Nine Months Ended October 2, 2015 Net Income | Per Diluted Share | October 3, 2014 Net Income | Per Diluted Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net income as reported | $22 | $— | $14,012 | $0.54 | $17,313 | $0.66 | $41,282 | $1.60 |
| Adjustments: |  |  |  |  |  |  |  |  |
| Amortization of intangibles(a)(c) | 2,271 | 0.09 | 2,379 | 0.09 | 6,996 | 0.27 | 7,205 | 0.28 |
| Inventory step-up amortization (COS)(c) | — | — | 57 | — | — | — | 57 | — |
| IP related litigation (SG&A)(b)(c) | 733 | 0.03 | 503 | 0.02 | 2,136 | 0.08 | 998 | 0.04 |
| Consolidation and optimization expenses (OOE)(c)(d) | 4,523 | 0.17 | 2,508 | 0.10 | 15,422 | 0.58 | 3,763 | 0.15 |
| Acquisition and integration (income) expenses (OOE)(c)(e) | 4,845 | 0.18 | 87 | — | 4,961 | 0.19 | (161) | (0.01) |
| Asset dispositions, severance and other (OOE)(c)(f) | 2,468 | 0.09 | 1,489 | 0.06 | 3,600 | 0.14 | 2,276 | 0.09 |
| Lake Region Medical transaction costs (interest expense)(c)(g) | 3,112 | 0.12 | — | — | 3,112 | 0.12 | — | — |
| Gain on cost and equity method investments, net (other income, net)(c)(h) | (2,976) | (0.11) | (2,044) | (0.08) | (3,327) | (0.13) | (2,551) | (0.10) |
| R&D Tax Credit(i) | 400 | 0.02 | 400 | 0.02 | 1,200 | 0.05 | 1,200 | 0.05 |
| Adjusted net income and diluted EPS(j) | $15,398 | $0.58 | $19,391 | $0.75 | $51,413 | $1.95 | $54,069 | $2.09 |
| Adjusted diluted weighted average shares | 26,441 |  | 25,923 |  | 26,372 |  | 25,850 |  |

(a) Given our acquisition of Lake Region Medical in the fourth quarter of 2015 and in order to present our financial results in a form more comparable to other medical device companies and less acquisitive companies, during the third quarter of 2015 we began excluding intangible asset amortization for purposes of calculating adjusted net income and adjusted diluted EPS. Prior period adjusted amounts have been recalculated to exclude intangible amortization for all periods presented.

(b) In 2013, we filed suit against one of our cardiac/neuromodulation competitors alleging they were infringing on our intellectual property. Given the complexity and significant costs incurred pursuing this litigation, during the second quarter of 2015, we began excluding these litigation expenses from adjusted amounts. Total costs expected to be incurred in connection with this litigation in 2015 is between $4 million and $5 million pre-tax. We expect this matter to proceed to trial during the first quarter of 2016. Prior period adjusted amounts have been recalculated to exclude these costs for all periods presented.

(c) Net of tax amounts computed using a 35% U.S., Mexico, and France statutory tax rate, a 25% Uruguay statutory tax rate, and a 0% tax rate for Swiss adjustments. Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.

(d) During 2015 and 2014, we incurred costs primarily related to the transfer of our portable medical and vascular manufacturing operations to Tijuana, Mexico.

(e) During 2015, we incurred transaction costs related to the acquisition of Lake Region Medical ($5.1 million pre-tax) and the integration of CCC Medical Devices. During 2014, we incurred costs (income) related to the integration of CCC Medical Devices and NeuroNexus Technologies.

(f) 2015 costs primarily include legal and professional fees incurred in connection with the proposed spin-off of Nuvectra ($3.1 million pre-tax during the third quarter of 2015 and $4.6 million pre-tax for the first nine months of 2015). 2014 costs primarily include costs in connection with our business reorganization to realign our contract manufacturing operations.

(g) During the third quarter of 2015, we recorded $4.8 million pre-tax of transaction costs (i.e. debt commitment fees, interest rate swap termination costs) in connection with our acquisition of Lake Region Medical.

(h) Pre-tax amount is a gain of $4.6 million and $5.1 million for the 2015 quarter and year-to-date periods, respectively, and a gain of $3.1 million and $3.9 million for the 2014 quarter and year-to-date periods, respectively.

(i) The Federal R&D tax credit has not yet been extended for 2015. The 2014 Federal R&D tax credit was enacted in the fourth quarter of 2014. Amounts assume that the tax credit was effective at the beginning of the year for 2015 and 2014.

(j) The per share data in this table has been rounded to the nearest $0.01 and therefore may not sum to the total.

- 31 -

GAAP net income for the third quarter and first nine months of 2015 decreased 100% and 58%, respectively. Adjusted net income for the third quarter and first nine months of 2015 decreased 21% and 5%, respectively. GAAP and adjusted diluted EPS for the third quarter of 2015 were $0.00 and $0.58, respectively, compared to $0.54 and $0.75, respectively, for the third quarter of 2014. For the first nine months of 2015, GAAP and adjusted diluted EPS were $0.66 and $1.95, respectively, compared to $1.60 and $2.09, respectively, for the same period of 2014. These results are primarily due to the following:

#### Third Quarter 2015

- A $6.5 million, or 11%, decrease in gross profit due to lower sales volumes partially offset by higher gross profit as a percentage of sales, which increased 140 basis points to 35.2%, primarily due to higher selling prices and lower performance-based compensation expense;
- A $0.6 million, or 5%, increase in net research, development and engineering (“RD&E”) costs primarily due to a decrease in customer cost reimbursements due to the timing of achievement of customer milestones;
- The decrease in GAAP net income and EPS was also attributable to a $2.3 million increase in costs incurred in connection with our 2014 initiatives to invest in capacity and capabilities, $5.1 million of transaction costs incurred in connection with our acquisition of Lake Region Medical and $3.1 million of professional fees incurred in connection with the Spin-off. These costs are included in GAAP other operating expenses, net, but are excluded from adjusted amounts;
- The decrease in GAAP net income and EPS was also attributable to $4.8 million of transaction costs (i.e. debt commitment fees, interest rate swap termination costs) incurred in connection with our acquisition of Lake Region Medical. These costs are included in GAAP interest expense, net, but are excluded from adjusted amounts; and
- The decrease in GAAP net income and EPS was partially offset by a $1.4 million increase in income from our cost and equity method investments. This income is included in GAAP other income, net, but is excluded from adjusted amounts.

#### First Nine Months 2015

- A $12.2, or 7%, decrease in gross profit due to lower sales volumes partially offset by lower performance-based compensation expense;
- A $3.3 million, or 5%, increase in selling, general, and administrative (“SG&A”) expenses was partially attributable to the acquisition of CCC, which added $0.8 million of SG&A costs, ramping up our QiG medical device infrastructure of $1.8 million, as well as higher legal fees in connection with IP related litigation of $1.8 million, which are excluded from adjusted amounts. These increases were partially offset by lower performance-based compensation expense of $1.9 million;
- The decrease in GAAP net income was also attributable to a $12.8 million increase in costs incurred in connection with our 2014 initiatives to invest in capacity and capabilities, $5.1 million of transaction costs incurred in connection with our acquisition of Lake Region Medical and $4.6 million of professional fees incurred in connection with the Spin-off. These costs are included in GAAP other operating expenses, net, but are excluded from adjusted amounts;
- The decrease in GAAP net income and EPS was also attributable to $4.8 million of transaction costs (i.e. debt commitment fees, interest rate swap termination costs) incurred in connection with our acquisition of Lake Region Medical. These costs are included in GAAP interest expense, net, but are excluded from adjusted amounts;
- The decrease in GAAP net income and EPS was partially offset by a $1.2 million increase in income from our cost and equity method investments and $1.1 million of foreign currency exchange rate gains due to the strengthening of the U.S. dollar relative to the Euro. Cost and equity method investment gains and losses are included in GAAP other income, net, but are excluded from adjusted amounts.
- The changes in the GAAP and adjusted effective tax rates was primarily due to higher income in lower tax rate jurisdictions in 2015 versus 2014; and
- An increase in weighted average diluted shares outstanding as a result of the increase in our stock price and stock issued under our stock-based compensation programs. This increase reduced the 2015 year-to-date GAAP diluted EPS by $0.01 and adjusted diluted EPS by $0.04.
- 32 -

*(dollars in thousands)*

|  | Three Months Ended October 2, 2015 | October 3, 2014 | Nine Months Ended October 2, 2015 | October 3, 2014 |
| --- | ---: | ---: | ---: | ---: |
| Net income as reported | $22 | $14,012 | $17,313 | $41,282 |
| Interest expense | 5,825 | 1,051 | 8,151 | 3,208 |
| Provision (benefit) for income taxes | (16) | 4,888 | 4,448 | 17,811 |
| Depreciation | 5,504 | 5,808 | 16,933 | 17,405 |
| Amortization | 3,243 | 3,487 | 10,008 | 10,451 |
| EBITDA | 14,578 | 29,246 | 56,853 | 90,157 |
| Inventory step-up amortization | — | 87 | — | 87 |
| IP related litigation | 1,127 | 773 | 3,286 | 1,535 |
| Stock-based compensation expense | 3,027 | 3,509 | 8,999 | 10,238 |
| Consolidation and optimization expenses | 5,473 | 3,752 | 19,202 | 6,970 |
| Acquisition and integration expenses (income) | 5,202 | 133 | 5,366 | (248) |
| Asset dispositions, severance and other | 3,169 | 2,291 | 4,881 | 3,501 |
| Noncash (gain) loss on cost and equity method investments | (1,178) | 35 | (1,718) | (745) |
| Adjusted EBITDA | $31,398 | $39,826 | $96,869 | $111,495 |
| Adjusted EBITDA as a % of sales | 21.4% | 23.2% | 20.1% | 21.5% |

During the third quarter of 2015, we have begun presenting adjusted EBITDA in our SEC documents along with our financial results in order to provide information more consistent with other medical device companies. In addition, these adjusted EBITDA calculations are similar to the debt covenant calculations under our new secured credit facilities. The primary driver behind the decreases in adjusted EBITDA for the third quarter and year-to-date periods of 2015 versus the comparable 2014 periods are the same factors which drove the decreases in adjusted diluted EPS as discussed above.

### Financial Guidance

Our guidance for fiscal year 2015 is as follows:

| Sales Foreign Currency Impact on Sales Capital Expenditures GAAP Effective Tax Rate Adjusted Effective Tax Rate Previous Adjusted Diluted EPS Guidance Intangible Amortization New Adjusted Diluted EPS Guidance GAAP Diluted EPS | $685 - $695 million $14 - $15 million $40 - $50 million ~22% ~20% - 22% $2.61 - $2.71 $0.35 - $0.35 $2.96 - $3.06 $1.32 - $1.42 |
| --- | ---: |
| Diluted Weighted Average Shares | 26,500,000 |

We expect to be at the lower end of our adjusted diluted EPS guidance as we expect the impact of our reduced revenue will be partially offset by our cost savings and consolidation initiatives.

The above guidance does not include the impact of the Lake Region Medical acquisition, which is expected to be dilutive to GAAP diluted EPS due to approximately $25 million of transaction related expenses that is expected to be incurred in the fourth quarter of 2015. Additionally, we expect Lake Region Medical to be 5% to 10% dilutive to adjusted diluted EPS for 2015 due to the incremental interest expense and approximately 5.0 million shares issued in connection with the transaction. We expect to achieve net annual synergies of $25 million in 2016, which is expected to increase to at least $60 million in 2018.

- 33 -

Given our acquisition of Lake Region Medical and in order to present our results in a manner more comparable to other medical device and less acquisitive companies, our adjusted diluted EPS guidance now adds back the amortization of intangible assets of approximately $0.35 per diluted share for 2015, which does not include the additional intangible amortization expense expected from Lake Region Medical.

Our adjusted diluted EPS guidance excludes the following:

- Consolidation and optimization, acquisition and integration, asset write-down, and Spin-off related charges of approximately $35 million ($28.5 million net of tax) or $1.08 per diluted share.
- IP related litigation SG&A expenses of approximately $4.5 million ($2.9 million net of tax) or $0.11 per diluted share.
- Lake Region Medical transaction-related expenses incurred during the third quarter of 2015 and included in interest expense of approximately $6.8 million ($4.4 million net of tax) or $0.17 per diluted share.
- Gain on investment of cost and equity method investments of approximately $5.1 million ($3.3 million net of tax) or $0.13 per diluted share. and

Our adjusted diluted EPS guidance includes the Federal research and development tax credit of approximately $1.6 million or $0.06 per diluted share, which has not yet been enacted for 2015.

We continue to expect to receive FDA approval for our Algovita spinal cord stimulator in the fourth quarter of 2015 and expect to complete the Spin-off during the first quarter of 2016. Once effective, the Spin-off will deliver Greatbatch improved financial performance through our long-term manufacturing agreement with Nuvectra for the supply of Algovita and lower operating expenses estimated in the range of $12 million to $16 million on an annualized basis.

### Our CEO’s View

We are disappointed by our current quarter results, however we remain very optimistic about the future growth prospects of Greatbatch. We continue to drive the implementation of our strategy to create shareholder value, which includes our transformative acquisition of Lake Region Medical, as well as the spin-off of Nuvectra. The acquisition of Lake Region Medical will provide a substantially more comprehensive portfolio of technologies and services for our customers while the spin-off will provide both Greatbatch and Nuvectra with the focus and flexibility needed to execute their distinct strategies. Our customer relationships continue to be strong and we are well positioned to achieve a record fourth quarter performance.

There were several factors and external headwinds that drove our revenue decline for the third quarter of 2015. The discrete factors included the timing of new product introductions and end of life products, which do not always line up on a quarterly basis, and resulted in a net negative impact. Another external headwind we are facing is that our customers continue to reduce their inventory levels, the majority of the impact of which we believe is behind us. Additionally, our revenues continue to be impacted by foreign currency exchange rates and the slowdown in the energy markets. These were the primary factors driving our lowered full year revenue forecast to $685 million to $695 million. However, we are maintaining our adjusted diluted EPS guidance range with the expectation of being at the lower end of that range, as we expect the impact of our reduced revenue will be partially offset by our cost savings and consolidation initiatives.

### Product Development

### Greatbatch Medical

Our core business is well positioned because our OEM customers leverage our portfolio of intellectual property, and we continue to build a healthy pipeline of diverse medical technology opportunities. These product development opportunities, when combined with the investments we have made in our sales and marketing resources, are expected to allow us to meet our long-term five percent revenue growth objective. Some of the more significant product development opportunities Greatbatch Medical is pursuing are as follows:

- 34 -

| Product Line | Product Development Opportunities |
| --- | --- |
| Cardiac/ Neuromodulation | Developing next generation technology programs including Gen 2 QHR battery, next generation filtered feedthroughs, and high voltage capacitors. |
| Orthopaedic | Developing next generation reamers, hip and bone preparation instruments, as well as disposable kits, and power solutions for surgical tools. |
| Portable Medical | Developing proprietary power solutions for various surgical, diagnostic and other market categories where device mobility is critical, including sterilized surgical products, wireless power and battery management technologies. |
| Vascular | Developing introducer technologies to expand into new clinical markets, as well as expanding current introducer and catheter platforms to better serve existing clinical markets and customers. |
| Energy, Military, Environmental | Developing power solutions to advance performance and reliability of battery packs in critical environments. |

### QiG

Through QiG, we provide our Greatbatch Medical customers with complete medical device systems. This medical device strategy includes strategic equity investments and medical device technology and products developed independently, as well as in conjunction with our OEM partners. While we do not intend to discuss each of these projects individually, we will discuss significant milestones as they occur.

Algovita, our SCS system to treat chronic intractable pain of the trunk and/or limbs, was designed to target unmet clinical needs with a focus on safety and product differentiation for all user groups. This product was submitted for premarket approval (“PMA”) to the United States Food & Drug Administration (“FDA”) in December 2013, and in January 2014 documentation for European CE Mark was submitted to the notified body, TÜV SÜD America. CE Mark approval was received in June 2014. In April 2015, we announced receipt of a letter from the FDA informing us that our PMA application for Algovita is approvable subject to completion of an FDA inspection that finds that the manufacturing facilities, methods and controls used in the production of Algovita comply with the applicable requirements of the FDA’s Quality System Regulation. During the fourth quarter of 2015, we announced that we successfully completed our pre-PMA inspection. We expect to obtain final approval of our PMA application for Algovita during the fourth quarter of 2015 and to launch Algovita commercially in the United States shortly thereafter.

QiG intends to modify the Algovita platform for other established indications in growing and emerging technologies such as SNS and DBS, among others. We have a large and growing list of interested partners in the neuromodulation space that we can engage. Additionally we are leveraging NeuroNexus and CCC for early stage research and development. Lastly, we will continue to advance and incorporate the capabilities from our core Greatbatch Medical segment across opportunities in neurostimulation.

### Cost Savings and Consolidation Efforts

In 2015 and 2014, we recorded charges in other operating expenses, net related to various cost savings and consolidation initiatives. These initiatives were undertaken to improve our operational efficiencies and profitability, the most significant of which are as follows (dollars in millions):

| Initiative 2014 investments in capacity and capabilities | Expected Expense $29 - $34 | Expected Capital $25 - $28 | Expected Benefit to Operating Income(a) \> $20 | Expected Completion Date 2016 |
| --- | ---: | ---: | --- | --- |
| 2013 operating unit realignment | $6.6 | — | \> $7 | Completed |
| Orthopaedic optimization | $45 - $48 | $30 - $35 | $15 - $20 | 2011 - 2017 |

(a) Represents the annual benefit to our operating income expected to be realized from these initiatives through cost savings and/or increased capacity. These benefits will be phased in over time as the various initiatives are completed.

See Note 9 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about the timing, cash flow impact and amount of future expenditures for these initiatives. We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. Future charges are expected be incurred as a result of the consolidation and optimization of the combined Greatbatch and Lake Region Medical businesses.

- 35 -

We currently expect to achieve annual pre-tax operating synergies in connection with the Lake Region Medical Acquisition of $25 million in 2016, which is expected to increase to at least $60 million by 2018. In order to achieve these synergies we expect the investment necessary to be $69 million, which consists of $22 million in capital expenditures and $47 million of operating expenses, over a period of three years following completion of the acquisition.

### Our Financial Results

We utilize a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. For 52-week years, each quarter contains 13 weeks. The third quarter and first nine months of 2015 and 2014 ended on October 2, and October 3, respectively, and each contained 13 weeks and 39 weeks, respectively. The discussion that follows should be read in conjunction with our Condensed Consolidated Financial Statements and related notes and with the Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the fiscal year ended January 2, 2015. The following table presents certain selected financial information derived from our Condensed Consolidated Financial Statements for the periods presented (dollars in thousands, except per share data):

| Sales: Greatbatch Medical | Three Months Ended October 2, 2015 | October 3, 2014 | Change $% |  | Nine Months Ended October 2, 2015 | October 3, 2014 | Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cardiac/Neuromodulation | $72,961 | $85,618 | $(12,657) | (15)% | $239,387 | $252,403 | $(13,016) | (5)% |
| Orthopaedic | 27,752 | 32,489 | (4,737) | (15)% | 102,204 | 106,785 | (4,581) | (4)% |
| Portable Medical | 17,224 | 17,199 | 25 | —% | 48,591 | 53,139 | (4,548) | (9)% |
| Vascular | 14,107 | 14,903 | (796) | (5)% | 37,370 | 43,210 | (5,840) | (14)% |
| Energy, Military, Environmental | 11,977 | 19,016 | (7,039) | (37)% | 46,232 | 58,499 | (12,267) | (21)% |
| Total Greatbatch Medical | 144,021 | 169,225 | (25,204) | (15)% | 473,784 | 514,036 | (40,252) | (8)% |
| QiG | 2,776 | 2,474 | 302 | 12% | 10,564 | 4,025 | 6,539 | 162% |
| Elimination of intersegment sales(a) | (160) | — | (160) | NA | (1,501) | — | (1,501) | NA |
| Total sales | 146,637 | 171,699 | (25,062) | (15)% | 482,847 | 518,061 | (35,214) | (7)% |
| Cost of sales | 94,991 | 113,581 | (18,590) | (16)% | 320,852 | 343,877 | (23,025) | (7)% |
| Gross profit | 51,646 | 58,118 | (6,472) | (11)% | 161,995 | 174,184 | (12,189) | (7)% |
| Gross profit as a % of sales | 35.2% | 33.8% |  |  | 33.5% | 33.6% |  |  |
| Selling, general and administrative expenses (SG&A) | 22,308 | 22,121 | 187 | 1% | 69,021 | 65,753 | 3,268 | 5% |
| SG&A as a % of sales | 15.2% | 12.9% |  |  | 14.3% | 12.7% |  |  |
| Research, development and engineering costs, net (RD&E) | 14,299 | 13,638 | 661 | 5% | 39,907 | 39,962 | (55) | —% |
| RD&E as a % of sales | 9.8% | 7.9% |  |  | 8.3% | 7.7% |  |  |
| Other operating expenses, net | 13,844 | 6,176 | 7,668 | 124% | 29,449 | 10,223 | 19,226 | 188% |
| Operating income | 1,195 | 16,183 | (14,988) | (93)% | 23,618 | 58,246 | (34,628) | (59)% |
| Operating margin | 0.8% | 9.4% |  |  | 4.9% | 11.2% |  |  |
| Interest expense, net | 5,825 | 1,051 | 4,774 | 454% | 8,151 | 3,208 | 4,943 | 154% |
| Other income, net | (4,636) | (3,768) | (868) | NA | (6,294) | (4,055) | (2,239) | 55% |
| Provision (benefit) for income taxes | (16) | 4,888 | (4,904) | (100)% | 4,448 | 17,811 | (13,363) | (75)% |
| Effective tax rate | NA | 25.9% |  |  | 20.4% | 30.1% |  |  |
| Net income | $22 | $14,012 | $(13,990) | (100)% | $17,313 | $41,282 | $(23,969) | (58)% |
| Net margin | —% | 8.2% |  |  | 3.6% | 8.0% |  |  |
| Diluted earnings per share | $— | $0.54 | $(0.54) | (100)% | $0.66 | $1.60 | $(0.94) | (59)% |

(a) Intersegment sales between Greatbatch Medical and QiG are eliminated in consolidation and are included in Greatbatch Medical’s cardiac and neuromodulation product line.

### Greatbatch Medical Sales

Total Greatbatch Medical sales for the third quarter and first nine months of 2015 decreased 15% and 8%, respectively, over the comparable 2014 periods. The most significant contributors to these results were as follows:

Cardiac and neuromodulation sales for the third quarter and first nine months of 2015 decreased 15% and 5%, respectively, in comparison to the prior year. This decrease reflects the impact of customer inventory management programs, the timing of new

- 36 -

product introductions and faster than anticipated runoff of end of life products, as well as tough comparables versus the prior year. These decreases were partially offset by new product introductions, primarily from our neuromodulation products. It should be noted that revenue from end of life products can be lumpy in nature and tend to run off over several years. We expect fourth quarter cardiac and neuromodulation sales to improve significantly in comparison to the prior year fourth quarter as customer ordering patterns recover, new product introductions ramp, and due to easier comparables versus the 2014 fourth quarter. Growth in our cardiac and neuromodulation product line for 2016 will continue to be negatively impacted by the end of life on legacy products, as well as continued pressure from our customer’s inventory management initiatives. However, the impact of these headwinds is expected to be partially mitigated by growth from new products, and in particular, neuromodulation new product introductions.

Orthopaedic sales for the third quarter and first nine months of 2015 decreased 15% and 4%, respectively, in comparison to the prior year. Foreign currency exchange rate fluctuations reduced orthopaedic sales by approximately $2.5 million in comparison to the prior year third quarter ($12 million year-to-date) due to the strengthening dollar versus the Euro. On an organic constant currency basis, in comparison to the prior year third quarter and year-to-date orthopaedic sales decreased 7% and increased 7%, respectively. This quarter over quarter decrease reflects the impact of customer inventory management programs, as well as the timing of customer product launches. The organic constant currency increase in orthopaedic sales for the first nine months of 2015 was primarily driven by market growth, new customer wins, and our investments in capacity and capabilities at our Chaumont, France facility. Orthopaedic sales are expected to improve in the fourth quarter as instrument sales tend to be lumpy and are typically tied to customer product launches. We expect foreign currency exchange rate fluctuations to reduce full year 2015 orthopaedic sales by $14 to $15 million.

Third quarter 2015 portable medical sales stabilized and were consistent with the third quarter of 2014. For the first nine months of 2015, portable medical sales decreased 9% as we are refocusing our product line offerings in the portable medical space to products that have higher profitability. Correspondingly, we have discontinued or reduced volumes in certain of our lower margin products. As part of our investment in capacity and capabilities and to better align our resources, during 2014, we announced plans to transfer our portable medical operations into a new facility located in Tijuana, Mexico, which is expected to be substantially completed by the end of the first quarter of 2016. We expect this product line to resume growth in the fourth quarter of 2015 as customers build safety stock in anticipation of the product line transfer. We expect our product line transfer to Mexico will position us to be more competitive in both new and existing markets.

Vascular sales for the third quarter and first nine months of 2015 decreased 5% and 14%, respectively, in comparison to the prior year primarily due to the timing of new product introductions and end of life on legacy products. We expect this product line to resume growth in the fourth quarter as customers build safety stock in anticipation of the product line transfer and as new product introductions begin to ramp. As part of our investment in capacity and capabilities and to better align our resources, during 2014, we announced plans to transfer our catheter and introducer operations into our Tijuana, Mexico facility, which is expected to be substantially completed in the first half of 2016. We expect our product line transfer to Mexico will position us to be more competitive in both new and existing markets.

Energy, military, and environmental (“EME”) sales for the third quarter and first nine months of 2015 decreased 37% and 21%, respectively, in comparison to the prior year due to the slowdown in the energy markets, which has caused customers to reduce drilling and exploration volumes. The slowdown in the energy markets is expected to impact our EME sales for at least the next three quarters.

### QiG Sales

QiG sales for the third quarter and first nine months of 2015 increased $0.3 million and $6.5 million, respectively, in comparison to the prior year periods. Sales for the third quarter and first nine months of 2015 include $1.5 million and $6.6 million, respectively, from CCC, which was acquired in August 2014. On an organic constant currency basis, 2015 third quarter QiG sales remained relatively consistent with the prior year. On an organic constant currency basis, 2015 year-to-date QiG sales increased 27% primarily due to new product launches including a limited release of Algovita in Europe and the NeuroNexus SmartBox™ portable control and data streaming system.

- 37 -

### Gross Profit

Changes to gross profit as a percentage of sales from the prior year were due to the following:

|  | Change From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Performance-based compensation(a) | 0.7% | 0.6% |
| Production efficiencies, volume and mix(b) | 0.3% | 0.5% |
| Impact of CCC(c) | (0.3)% | (0.3)% |
| Price(d) | 0.6% | (0.3)% |
| Other | 0.1% | (0.6)% |
| Total percentage point change to gross profit as a percentage of sales | 1.4% | (0.1)% |

(a) Amounts represents the change in performance-based compensation versus the prior year period and is recorded based upon the actual results achieved.

(b) Our gross profit percentage benefited from higher production volumes and production efficiencies gained as a result of our investments in capacity and capabilities.

(c) Amounts represent the impact to our gross profit percentage related to the acquisition of CCC in August 2014.

(d) Our gross profit percentage for the first nine months of 2015 was negatively impacted by continued pricing pressure from our larger OEM customers. Our gross profit percentage for the third quarter of 2015 benefited from lower price discounts offered to customers in comparison to the prior year period.

### SG&A Expenses

Changes to SG&A expenses from the prior year were due to the following (in thousands):

|  | Change From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Performance-based compensation(a) | $(511) | $(1,945) |
| Legal fees(b) | 100 | 1,437 |
| G&A personnel costs(c) | 535 | 2,170 |
| Impact of CCC(d) | (160) | 845 |
| Other | 223 | 761 |
| Net increase in SG&A | $187 | $3,268 |

(a) Amounts represents the change in performance-based compensation versus the prior year period and is recorded based upon actual results achieved.

(b) Amounts represents the increase in legal costs compared to the prior year period and includes higher IP related defense costs, as well as other corporate initiatives. In 2013, we filed suit against one of our cardiac/neuromodulation competitors alleging they were infringing on our IP. Costs associated with this litigation accounted for $0.4 million and $1.8 million of the quarter and year-to-date increases in SG&A expenses, respectively, from 2014 to 2015. Total costs expected to be incurred in connection with this litigation in 2015 is between $4 million and $5 million. We expect this litigation to proceed to trial during the first quarter of 2016.

(c) Amounts represents various increases in general and administrative costs related to the growth of our business. Our QiG medical device business, excluding CCC, accounted for $0.6 million and $1.8 million of this increase for the quarter and year-to-date periods, respectively, as we continue to invest resources in connection with the commercialization of Algovita.

(d) Amount represents the incremental SG&A expenses related to the acquisition of CCC in August 2014.

- 38 -

### RD&E Expenses, Net

Net RD&E costs are comprised of the following (in thousands):

|  | Three Months Ended October 2, 2015 | October 3, 2014 | Nine Months Ended October 2, 2015 | October 3, 2014 |
| --- | ---: | ---: | ---: | ---: |
| Research, development and engineering costs | $15,551 | $15,303 | $44,654 | $45,837 |
| Less: cost reimbursements | (1,252) | (1,665) | (4,747) | (5,875) |
| Total RD&E, net | $14,299 | $13,638 | $39,907 | $39,962 |

Net RD&E costs for the 2015 third quarter increased $0.7 million versus the comparable 2014 period primarily due to lower customer cost reimbursements due to the timing of achievement of customer milestones. Net RD&E costs for the 2015 year-to-date period remained relatively consistent with the prior year as lower performance-based compensation was offset by lower customer cost reimbursements. The decrease in customer cost reimbursements for the first nine months of 2015 primarily relates to the expiration of certain government grants acquired in our NeuroNexus acquisition, which Greatbatch was not eligible to renew, as well as the timing of achievement of customer milestones.

### Other Operating Expenses, Net

Other operating expenses, net is comprised of the following (in thousands):

|  | Three Months Ended October 2, 2015 | October 3, 2014 | Nine Months Ended October 2, 2015 | October 3, 2014 |
| --- | ---: | ---: | ---: | ---: |
| 2014 investments in capacity and capabilities(a) | $5,116 | $2,787 | $17,854 | $5,005 |
| Orthopaedic optimization costs(a) | 357 | 996 | 1,348 | 1,032 |
| 2013 operating unit realignment(a) | — | (31) | — | 1,004 |
| Other consolidation and optimization income, net(a) | — | — | — | (71) |
| Acquisition and integration costs (income)(b) | 5,202 | 133 | 5,366 | (248) |
| Asset dispositions, severance and other(c) | 3,169 | 2,291 | 4,881 | 3,501 |
| Total other operating expenses (income), net | $13,844 | $6,176 | $29,449 | $10,223 |

(a) Refer to “Cost Savings and Consolidation Efforts” section of this Item and Note 9 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for disclosures related to the timing and level of remaining expenditures for these initiatives.

(b) During the third quarter of 2015, we incurred $5.1 million of transaction costs in connection with our acquisition of Lake Region Medical. During 2015 and 2014, we incurred costs (income) related to the integration of CCC and NeuroNexus. These expenses were primarily for travel costs in connection with integration efforts, consulting, training, and the change in fair value of the contingent consideration recorded in connection with the NeuroNexus acquisition, which resulted in a gain of $0.8 million during the first nine months of 2014.

(c) During 2015 and 2014, we recorded losses in connection with various asset disposals. In addition, total legal and professional costs incurred in connection with the proposed Spin-off during the first nine months of 2015 were $4.6 million ($3.1 million for the third quarter 2015). Expenses related to this initiative will be recorded within the applicable segment and corporate cost centers to which the expenditures relate. Refer to Note 15 “Business Segment, Geographic and Concentration Risk Information” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional discussion on the proposed Spin-off. The proposed transaction is expected to be completed in the first quarter of 2016.

During the first nine months of 2014, we recorded $2.0 million of charges in connection with our business reorganization to align our contract manufacturing operations. Those costs primarily related to consulting and IT development projects, which were completed in the fourth quarter of 2014. Additionally, during the third quarter of 2014, we also incurred $0.8 million of expense related to the separation from service of the Company's Senior Vice President, Human Resources.

We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. Other operating expenses, net for 2015 are expected to be approximately $55 million to $60 million. This includes approximately $25 million of Lake Region Medical acquisition costs and $5 million to $10 million in transaction-related costs for the proposed Spin-Off.

- 39 -

### Interest Expense, Net

Interest expense, net for the third quarter and first nine months of 2015 increased $4.8 million and $4.9 million, respectively, in comparison to the prior year periods. This increase was primarily due to $4.8 million of transaction costs (debt commitment fees and interest rate swap termination costs) incurred in connection with our acquisition of Lake Region Medical. Going forward, interest expense will increase significantly due to the $1.8 billion of debt borrowed in connection with the Lake Region Medical acquisition. See Note 17 “Subsequent Events” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information regarding this transaction and the debt borrowed.

### Other Income, Net

Other income, net includes income realized on our cost and equity method investments, which increased $1.4 million and $1.2 million for the third quarter and first nine months of 2015, respectively, in comparison to prior year periods. Other income, net also includes the impact of foreign currency exchange rate fluctuations on transactions denominated in foreign currencies, which decreased $0.5 million and increased $1.1 million during the third quarter and first nine months of 2015, respectively, compared to the same periods of 2014, primarily due to the strengthening of the U.S. dollar relative to the Euro which began in the second half of 2014 and stabilized during the second half of 2015. We generally do not expect foreign currency exchange rate fluctuations to have a material impact on our results of operations.

As of October 2, 2015 and January 2, 2015, we held $22.6 million and $14.5 million, respectively, of investments in equity and other securities that are accounted for as either cost or equity method investments. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest our investment may not be recoverable. These investments are in start-up research and development companies whose fair value is highly subjective in nature and could be subject to significant fluctuations in the future that could result in material gains or losses.

### Provision for Income Taxes

The 2015 GAAP effective tax rate for the first nine months of 2015 was 20.4% compared to 30.1% for the same period of 2014. This decrease was primarily attributable to higher income in lower tax rate jurisdictions. The 2015 and 2014 GAAP effective tax rates do not include the benefit of the Federal research and development tax credit, but we assume the benefit of this credit when calculating our adjusted diluted EPS. If enacted, the research and development tax credit would benefit the current year GAAP provision for income taxes by approximately $1.6 million or $400 thousand per quarter and would be recognized in the quarter the legislation is enacted.

We expect there to be continued volatility of this effective tax rate due to several factors, including the impact of the Lake Region Medical acquisition, changes in the mix of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. We continuously evaluate and currently have various tax planning initiatives in place that are aimed at reducing our effective tax rate over the long-term.

### Government Regulation

The Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively “Health Care Reform”) legislated broad-based changes to the U.S. healthcare system that could significantly impact our business operations and financial results, including higher or lower revenue, as well as higher employee medical costs and taxes. Health Care Reform imposes significant new taxes on medical device OEMs, which will result in a significant increase in the tax burden on our industry and which could have a material negative impact on our financial condition, results of operations and our cash flows. Other elements of Health Care Reform such as comparative effectiveness research, an independent payment advisory board, payment system reforms including shared savings pilots and other provisions could meaningfully change the way healthcare is developed and delivered, and may materially impact numerous aspects of our business, results of operations and financial condition. Many significant parts of Health Care Reform will be phased in over the next several years and require further guidance and clarification in the form of regulations. The medical device tax, which was effective in 2013, increased our cost of sales by $0.4 million for the first nine months of 2015.

In the first quarter of 2014, we initiated a voluntary field corrective action for all Standard Offset Cup Impactors after an internal review determined that the sterilization recommendation in the Instructions For Use for the product did not meet requirements for sterility assurance, which has the potential to result in surgical infection. We have validated two sterilization parameters that meet acceptable sterility assurance levels and provided them to affected customers. We have informed the FDA and other government agencies of this action, which impacts all Standard Offset Cup Impactors manufactured and distributed from 2004 to 2013. Greatbatch has received three complaints possibly related to this issue, however no adverse events have been reported. Future customer complaints or negative regulatory actions regarding this product or any of our products could harm our operating results or financial condition.

- 40 -

### Liquidity and Capital Resources

*(Dollars in thousands)*

|  | As of October 2, 2015 | January 2, 2015 |
| --- | ---: | ---: |
| Cash and cash equivalents | $68,594 | $76,824 |
| Working capital | $246,822 | $242,022 |
| Current ratio | 3.10 | 3.23 |

The decrease in cash and cash equivalents and current ratio from the end of 2014 was primarily due to our investment of $37.6 million in property, plant and equipment and cost and equity method investments during the first three quarters of 2015 partially offset by cash flow from operations of $31.0 million. The increase in our working capital during the first three quarters of 2015 was primarily a result of the cash generated by operations, which was used to build inventory in anticipation of higher sales volumes in the fourth quarter of 2015. Of the $68.6 million of cash and cash equivalents on hand as of October 2, 2015, $18.8 million is being held at our foreign subsidiaries and is considered permanently reinvested.

***Credit Facilities –*** As of October 2, 2015, we had a credit facility (the “Credit Facility”) that provided a $300 million revolving credit facility (the “Revolving Credit Facility”), a $180 million term loan (the “Term Loan”), a $15 million letter of credit subfacility, and a $15 million swingline subfacility. The principal of the Term Loan was payable in quarterly installments. In connection with the acquisition of Lake Region Medical, during the fourth quarter of 2015, we replaced the Credit Facility and Term Loan with new senior secured credit facilities and completed a senior notes offering. See Note 17 “Subsequent Events” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further description of this transaction and the significant impact it will have on the Company’s outstanding debt.

The new senior secured credit facilities (the “Senior Secured Credit Facilities”) consist of (i) a $200 million revolving credit facility (the “New Revolving Credit Facility”), which remained undrawn at the close of the acquisition, (ii) a $375 million term loan A facility (the “TLA Facility”), and (iii) a $1,025 million term loan B facility (the “TLB Facility”). In connection with the acquisition, we also completed a private offering of $360 million aggregate principal amount of 9.125% senior notes due on November 1, 2023 (the “Senior Notes”). The TLA Facility and TLB Facility were funded in full on October 27, 2015, and used, together with cash on hand and the net proceeds from the Senior Notes to fund the cash portion of the consideration transferred, to repay the outstanding debt of Lake Region Medical at closing, and to repay the Term Loan. The New Revolving Credit Facility will mature on October 27, 2020, the TLA Facility will mature on October 27, 2021 and the TLB Facility will mature on October 27, 2022.

The New Revolving Credit Facility and the TLA Facility contain covenants requiring (A) a maximum total net leverage ratio of 6.50:1.00, subject to step downs and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of not less than 3.00:1.00. The Senior Secured Credit Facilities include mandatory prepayments customary for credit facilities of its nature. The Senior Secured Credit Facilities are secured by the non-realty assets including cash, accounts receivable and inventories, of the Company’s direct and indirect wholly-owned domestic subsidiaries.

See Note 17 “Subsequent Events” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further description of Senior Secured Credit Facilities and Senior Notes.

***Operating Activities –*** Cash provided by operations of $31.0 million decreased 43% for the first nine months of 2015 versus the comparable 2014 period. This decrease was primarily due to $16.6 million of lower cash net income in comparison to the prior year as well as $7.1 million of higher working capital balances, primarily inventory, in anticipation of higher sales volumes in the fourth quarter of 2015. Immediately prior to the completion of the proposed Spin-off, Greatbatch expects to make a cash capital contribution of $75.0 million to Nuvectra, which is expected to help fund their operations for approximately two years. This amount is expected to be funded with cash on hand and/or availability under our New Revolving Credit Facility.

***Investing Activities –*** Net cash used in investing activities for the first nine months of 2015 was $36.9 million compared to $24.9 million in the comparable 2014 period. This included $31.3 million of cash used in 2015 for the purchase of property, plant, and equipment in connection with the consolidation and optimization initiatives discussed in Note 9 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report as well as routine capital expenditures. Our current expectation is that capital spending for 2015, excluding Lake Region Medical, will be in the range of $40 million to $50 million, of which half is discretionary in nature. We anticipate that cash on hand, cash flows from operations and available borrowing capacity under our New Revolving Credit Facility will be sufficient to fund these capital expenditures.

***Financing Activities –*** Net cash used in financing activities for the first nine months of 2015 was $1.8 million compared to $2.9 million in the comparable 2014 period. The net cash outflow for the first three quarters of 2015 included $6.0 million of

- 41 -

cash received from the exercise of stock options during the first nine months of 2015, which was partially offset by $7.5 million of principal payments on long-term debt.

***Capital Structure –*** After completion of the acquisition of Lake Region Medical, our capital structure consists of $1.76 billion of debt outstanding on our Senior Secured Credit Facilities and Senior Notes, and 30.6 million shares of common stock outstanding. We believe that this capital structure, along with our cash on hand, are sufficient to meet our short-term operating cash needs. If necessary, we currently have access to $200 million under our New Revolving Credit Facility and are authorized to issue 100 million shares of common stock and 100 million shares of preferred stock. We believe that, if needed, we can access public markets to raise additional capital. We have clear line of sight to the expected Lake Region Medical acquisition synergies and believe we will be able to service our debt and de-lever the company to 3.5 to 3 times our adjusted EBITDA over the next two to three years.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

### Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), SEC, Emerging Issues Task Force (“EITF”) or other authoritative accounting bodies to determine the potential impact they may have on our Condensed Consolidated Financial Statements. See Note 16 “Impact of Recently Issued Accounting Standards” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.

### Contractual Obligations

A table of our contractual obligations as of January 2, 2015 was included in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the fiscal year ended January 2, 2015. There have been no significant changes to our contractual obligations during the nine months ended October 2, 2015. See Note 11 “Commitments and Contingencies” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further discussion on our contractual obligations.

As a result of the Lake Region Medical acquisition, our contractual obligations have significantly changed since October 2, 2015. These changes will be incorporated into our disclosures for our Annual Report on Form 10-K for the fiscal year ending January 1, 2016.

### Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include statements relating to:

- future sales, expenses and profitability;
- future development and expected growth of our business and industry;
- our ability to execute our business model and our business strategy;
- our ability to identify trends within our industries and to offer products and services that meet the changing needs of those markets; and
- projected capital expenditures.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or “variations” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report. We are under no duty to update any of the forward-looking statements after the date of this report or to conform these statements to actual results.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the

- 42 -

following: our high level of indebtedness following the acquisition of Lake Region Medical, our inability to pay principal and interest on this high level of outstanding indebtedness, and the risk that this high level of indebtedness limits our ability to invest in our business and overall financial flexibility; our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement cost reduction and plant consolidation initiatives; our reliance on third party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high quality standards for our products; challenges to our intellectual property rights; product liability claims; product field actions or recalls; our inability to successfully consummate and integrate acquisitions, including the acquisition of Lake Region Medical, and to realize synergies and benefits from these acquisitions and to operate these acquired businesses in accordance with our expectations; our unsuccessful expansion into new markets; our failure to develop new products including system and device products; the timing, progress and ultimate success of pending regulatory actions and approvals, including with respect to Algovita; risks associated with the proposed spin-off of Nuvectra including our ability to execute the Spin-off successfully, the timing and taxable nature of the Spin-off, and the performance of Nuvectra post Spin-off; our inability to obtain licenses to key technology; regulatory changes, including Health Care Reform, or consolidation in the healthcare industry; global economic factors including currency exchange rates and interest rates; the resolution of various legal actions brought against the Company; and other risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of the Company’s Annual Report on Form 10-K and in other periodic filings with the SEC. Except as required by applicable law, the Company assumes no obligation to update forward-looking statements in this report whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

## Market risk

As filed, 5,705 characters.

***Foreign Currency –*** As of October 2, 2015, we had foreign operations in France, Mexico, Switzerland and Uruguay, which exposed us to foreign currency exchange rate fluctuations due to transactions denominated in Euros, Mexican pesos, Swiss francs and Uruguayan pesos, respectively. We continuously evaluate our foreign currency risk and will take action from time to time in order to best mitigate these risks, which includes the use of various derivative instruments such as forward currency exchange rate contracts. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency exposures would have had an impact of approximately $7 million on our annual sales as of October 2, 2015. This amount is not indicative of the hypothetical net earnings impact due to partially offsetting impacts on cost of sales and operating expenses in those currencies. We estimate that foreign currency exchange rate fluctuations during the nine months ended October 2, 2015 decreased sales in comparison to the 2014 period by approximately $12 million.

We have historically entered into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with a portion of the operations at our Tijuana, Mexico facility. These forward contracts were accounted for as cash flow hedges. The amount recorded during the nine months ended October 2, 2015 and October 3, 2014 related to our forward contracts was an increase in Cost of Sales of $1.2 million and a reduction in Cost of Sales of $0.2 million, respectively. No portion of the change in fair value of our foreign currency exchange rate contracts during the nine months ended October 2, 2015 or October 3, 2014 was considered ineffective. In connection with the Lake Region Medical acquisition, in October 2015 we terminated our outstanding foreign currency contracts resulting in a $2.4 million payment to the foreign currency contract counterparty. See Notes 11 “Commitments and Contingencies,” and 17 “Subsequent Events” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information regarding this transaction. As a result of the Lake Region Medical acquisition, we are currently reevaluating our foreign currency exchange rate risk exposures and will take steps to mitigate these exposures as appropriate.

We translate all assets and liabilities of our foreign operations, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translate sales and expenses at the average exchange rates in effect during the period. The net effect of these translation adjustments is recorded in the Condensed Consolidated Financial Statements as Comprehensive Income. The translation adjustment for the first nine months of 2015 and 2014 was a loss of $1.5 million and $2.4 million, respectively. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in our foreign subsidiaries. Net foreign currency transaction gains and losses included in Other Income, Net amounted to a gain of $1.6 million and $0.4 million for the first nine months of 2015 and 2014, respectively. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency net assets would have had an impact of approximately $1.5 million on our foreign net assets as of October 2, 2015.

***Interest Rates –*** Interest rates on our Credit Facility, reset, at our option, based upon the prime rate or LIBOR rate, thus subjecting us to interest rate risk. To help offset this risk, from time to time, we enter into receive floating-pay fixed interest rate swaps indexed to the same applicable index rate as the debt it is hedging. The receive variable leg of the interest rate swaps and the variable rate paid on the debt are expected to have the same rate of interest, excluding the credit spread, and reset and pay interest on the same dates. These swaps were accounted for as cash flow hedges.

- 43 -

In connection with our financing of the Lake Region Medical acquisition, the forecasted cash flows that the Company’s interest rate swaps were hedging were no longer expected to occur. As a result, during the third quarter of 2015, we recognized an additional $2.8 million in Interest Expense relating to the termination of the contracts. Subsequently, in October 2015, we terminated our outstanding interest rate swap agreements resulting in a $2.8 million payment to the interest rate swap counterparty. No portion of the change in fair value of our interest rate swaps during the nine months ended October 2, 2015 and October 3, 2014 was considered ineffective. The amount recorded as Interest Expense during the nine months ended October 2, 2015 and October 3, 2014 related to our interest rate swaps was $3.5 million and $0.3 million, respectively.

Of the $1.8 billion of debt borrowed in connection with the Lake Region Medical acquisition, only $360 million bears a fixed interest rate. Interest rates on the remaining $1.4 billion of debt under the Senior Secured Credit Facilities, reset, at our option, based upon the prime rate or LIBOR rate, thus subjecting us to interest rate risk. As a result of the Lake Region Medical acquisition, we are currently reevaluating our interest rate risk exposure and will take steps to mitigate this exposure as deemed by management to be appropriate. See Note 17 “Subsequent Events” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information regarding this transaction and the terms of the debt borrowed.

## Controls and procedures

As filed, 2,392 characters.

a. Evaluation of Disclosure Controls and Procedures

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the Securities and Exchange Commission as of October 2, 2015. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based on their evaluation, as of October 2, 2015, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting

We acquired the following subsidiary during 2014:

Centro de Construcción de Cardioestimuladores del Uruguay

We believe that the internal controls and procedures of the above mentioned subsidiary are reasonably likely to materially affect our internal control over financial reporting. We are currently in the process of incorporating the internal controls and procedures of this subsidiary into our internal controls over financial reporting.

The Company continues to extend its Section 404 compliance program under the Sarbanes-Oxley Act of 2002 (the “Act”) and the applicable rules and regulations under such Act to include this subsidiary. However, the Company has excluded this subsidiary from management’s assessment of the effectiveness of internal control over financial reporting as of January 2, 2015, as permitted by the guidance issued by the Office of the Chief Accountant of the Securities and Exchange Commission.

Other than as described above, there were no changes in the registrant’s internal control over financial reporting during our last fiscal quarter to which this Quarterly Report on Form 10-Q relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 9,406 characters.

On July 30, 2015, we announced our intentions to spin-off a portion of our QiG segment from the remainder of our business through a tax-free distribution of all of the shares QiG Group, LLC to the stockholders of Greatbatch on a pro rata basis (the “Spin-off”). Immediately prior to completion of the Spin-off, QiG Group LLC will be converted into a corporation organized under the laws of Delaware and change its name to Nuvectra Corporation (“Nuvectra”). We could be delayed or prevented from completing the proposed Spin-off, or be forced to complete it on terms or conditions that are less favorable and/or different than

- 44 -

expected, for a variety of reasons, including unanticipated developments, such as delays in obtaining regulatory approvals for Algovita, uncertainty of the financial markets, or challenges in establishing infrastructure and processes. Even if the transaction is completed, we may not realize some or all of the anticipated benefits from the proposed Spin-off. Moreover, following the proposed Spin-off, the combined value of the common stock of the two publicly-traded companies may not be equal to or greater than what the value of our common stock would have been had the proposed Spin-off not occurred. In addition, we expect to spend substantial time, money and effort on completing the proposed transaction without any assurance that it will be completed. Our investments in terms of financial and management resources may be significantly higher than expected, which could limit our ability to pursue other business opportunities and distract us from operating our businesses as currently conducted.

**In connection with the completion of the acquisition of Lake Region Medical, our indebtedness has increased significantly. Our indebtedness could limit our cash flow available for operations and our flexibility.**

In connection with the completion of the acquisition of Lake Region Medical, our indebtedness has increased significantly. In connection with the acquisition we raised $1.76 billion of debt and we had approximately $188.5 million available for borrowing under our revolving credit facility (after deducting approximately $11.5 million of letters of credit outstanding).

The degree to which we are leveraged could have important consequences to our stockholders, including the following:

- we may have greater difficulty satisfying our obligations with respect to our indebtedness;
- we must dedicate a substantial portion of our cash flow from operations to the payment of principal and interest on our indebtedness, reducing the funds available for our operations;
- our ability to obtain additional financing in the future for working capital, capital expenditures, acquisitions or other purposes may be impaired;
- our flexibility in planning for, or reacting to, changes in the markets in which we compete may be limited;
- we may be at a competitive disadvantage relative to our competitors with less indebtedness;
- we are rendered more vulnerable to general adverse economic and industry conditions; and
- we are exposed to increased interest rate risk given that a portion of our indebtedness obligations are at variable interest rates.

**We have incurred substantial expenses related to the acquisition of Lake Region Medical and will incur substantial expenses related to the integration of Lake Region Medical.**

We have incurred substantial expenses in connection with the acquisition of Lake Region Medical and will incur substantial expenses in connection with its integration. Specifically, we incurred approximately $5.1 million of transaction costs related to the acquisition of Lake Region Medical during the third quarter of 2015 and expect to incur an additional $25 million during the fourth quarter of 2015.

In addition, the investment necessary to achieve the annual pre-tax operating synergies of $25 million in 2016, which is expected to increase to at least $60 million in 2018, that we have estimated will result from the acquisition is currently estimated to be $69 million, which consists of $22 million in capital expenditures and $47 million of operating expenses, over a period of three years following completion of the acquisition. However, many of the expenses that will be incurred are, by their nature, difficult to estimate accurately. These expenses could, particularly in the near term, exceed the savings that we expect to achieve from elimination of duplicative expenses and the realization of economies of scale and cost savings. Although we expect that the realization of efficiencies related to the integration of Lake Region Medical’s business will offset incremental transaction, acquisition-related and restructuring costs over time, this net benefit may not be achieved in the near term, or at all.

**We may not be able to successfully integrate Lake Region Medical’s operations with our own or realize the anticipated benefits of the acquisition, which could materially and adversely affect our financial condition, results of operations and business prospects.**

We may not be able to successfully integrate Lake Region Medical’s operations with our own, and we may not realize all or any of the expected benefits of the acquisition as and when planned. The integration of Lake Region Medical’s operations with our own will be complex, costly and time consuming. We expect that it will require significant attention from senior management and will impose substantial demands on our operations and personnel, potentially diverting attention from other important pending projects. The difficulties and risks associated with the integration of Lake Region Medical include:

- customers, suppliers and other third parties with business relationships with our Company and/or Lake Region Medical may decide not to renew or may decide to seek to terminate, change and/or renegotiate their relationships with our Company and/or Lake Region Medical as a result of the acquisition, whether pursuant to the terms of their existing agreements with our Company and/or Lake Region Medical or otherwise;
- 45 -
- the possibility that we will fail to implement our business plans for the combined company;
- possible inconsistencies in the standards, controls, procedures, policies and compensation structures of the two companies;
- the increased scope and complexity of our operations;
- the potential loss of key employees and the costs associated with our efforts to retain key employees;
- provisions in our and Lake Region Medical’s contracts with third parties that may limit our flexibility to take certain actions;
- risks and limitations on our ability to consolidate corporate and administrative infrastructures of the two companies, including integrating the accounting systems and information systems of the two companies;
- the possibility that we may have failed to discover liabilities of Lake Region Medical during our due diligence investigation as part of the acquisition for which we, as a successor owner, may be responsible;
- obligations that we will have to counterparties of Lake Region Medical that arise as a result of the change in control of Lake Region Medical;
- obligations that we will have to holders of our senior notes and our lenders under our senior secured credit facilities, including our obligations to comply with our financial covenants; and
- the possibility of unanticipated delays, costs or inefficiencies associated with the integration of Lake Region Medical’s operations with our own.

As a result of these difficulties and risks, we may not accomplish the integration of Lake Region Medical’s business smoothly, successfully or within our budgetary expectations and anticipated timetable. Accordingly, we may fail to realize some or all of the anticipated benefits of the acquisition, such as increases in our scale, improvements in cash flows and operational efficiency and meaningful accretion to our financial results.

**Lake Region Medical was previously a private company and has not been required to comply with the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley”).**

Sarbanes-Oxley requires public companies to have and maintain effective internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements and to have management report on the effectiveness of those controls on an annual basis (and have its independent public accountants attest annually to the effectiveness of such internal controls). As a private company, Lake Region Medical was not required to comply with the requirements of Sarbanes-Oxley.

In connection with the completion of the acquisition, we are beginning to apply our Sarbanes-Oxley procedures regarding internal controls over financial reporting with respect to Lake Region Medical. This process will require a significant amount of time from our management and other personnel and will require us to expend a significant amount of financial resources, which is likely to increase our compliance costs. We will be required to assess Lake Region Medical’s internal controls over financial reporting at the end of 2016.

Other than as discussed above, there have been no material changes from the Company’s risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended January 2, 2015.

Filed Nov 10, 2015.
Source: SEC EDGAR, the filing index for accession 0001114483-15-000018. Last ingested by Listed: Nov 11, 2026, 00:08 ET. No prices; not investment advice.
